Geron price target raised to $5 from $4 at B. Riley

B. Riley analyst Kalpit Patel raised the firm’s price target on Geron to $5 from $4 and keeps a Buy rating on the shares. The company "hit a homerun" on overall efficacy with the Phase III trial of imetelstat, Patel tells investors in a research note. The data bolsters the analyst’s view on imetelstat’s profile in treating lower-risk myelodysplastic syndromes.